NCT05745233Enrolling by invitation
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
The Effect of Intraperitoneal Immune Checkpoint Inhibitor on Malignant Ascites of Patients With Gastric, Pancreatic or Biliary Tract Cancer
Source: ClinicalTrials.gov · Last updated 24 Aug 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This projectis aim to evaluate the efficacy of immune checkpoint inhibitor (pembrolizumab or nivolumab) on the malignant ascites of patients with advanced gastric, pancreatic and biliary tract cancers.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 16 Feb 2023
- Start date
- 1 Jan 2021
- Primary completion date
- Dec 2026
- Lead sponsor
- China Medical University Hospital
- NCT number
- NCT05745233
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Jan 2021 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are receiving intraperitoneal treatment for their malignant ascites including therapeutic paracentesis
- Patients who have serious concomitant systemic disorders incompatible with the study, i.e. poorly controlled diabetes mellitus, auto-immune disorders, cirrhosis of the liver, and the rest will be at the discretion of in-charged investigator
Other illness
- Patients have ascites which is related to causes other than the malignancies
- Patients with active infection
- Patients with bleeding disorders
- Patient with active cardiopulmonary disease or history of ischemic heart disease
Other
- Patients have intolerant abdominal pain
Who the study is looking for
- Patients have cyto-/histologically confirmed malignant ascites from gastric, pancreatic or biliary tract adenocarcinoma
- Patients have malignant ascites more than 1000ml
- Patients have no history of prior intraperitoneal therapy for malignant ascites
- Patients have life expectancy of at least 4 weeks
- Patients have adequate platelet count ≥ 50,000/ul
- Women or men of reproductive potential should agree to use an effective contraceptive method
- All patients must be informed of the investigational nature of this study and must sign written informed consents.
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| China Medical University Hospital Coordinator of this site? Confirm its status | Taichung | Taiwan | Unknown status |
Related publications
- Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer.Int J Clin Oncol · 2026 · PMID 41369826
This page is information, not medical advice. Discuss any trial with your doctor.